Astec Lifesciences Ltd
NSE: ASTEC BSE: 533138
₹623.70
(-0.66%)
Wed, 04 Mar 2026, 00:10 am
Market Cap13.9B
PE Ratio0
Dividend0
Process Industries
Chemicals: Agricultural
24.5KAstec Lifesciences Analysis
dividend
- Astec LifeSciences is not paying a notable dividend for India, therefore no need to check if the payments are increasing.
- No need to calculate the sustainability of Astec LifeSciences's dividends as it is not paying a notable one for India.
- Astec LifeSciences is not paying a notable dividend for India, therefore no need to check if the payments are stable.
- Astec LifeSciences's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Astec LifeSciences's dividend is below the markets top 25% of dividend payers in India (3.08%).
future
- Astec LifeSciences's earnings growth is expected to exceed the low risk savings rate of 7.2%.
- Astec LifeSciences's earnings are expected to exceed the low risk growth rate next year.
- Performance (ROE) is expected to be above the current IN Chemicals industry average.
- Astec LifeSciences's revenue growth is expected to exceed the India market average.
- Astec LifeSciences's earnings are expected to grow by 12.7% yearly, however this is not considered high growth (20% yearly).
- Astec LifeSciences's earnings growth is positive but not above the India market average.
- Astec LifeSciences's net income is expected to increase but not above the 50% threshold in 2 years time.
- Astec LifeSciences is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
- A decline in Astec LifeSciences's performance (ROE) is expected over the next 3 years.
- Astec LifeSciences's revenue is expected to increase but not above the 50% threshold in 2 years time.
- Astec LifeSciences's revenue is expected to grow by 10.7% yearly, however this is not considered high growth (20% yearly).
health
- Astec LifeSciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Astec LifeSciences is profitable, therefore cash runway is not a concern.
- Astec LifeSciences is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (170.6%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 3.4x debt.
- Astec LifeSciences's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (69.2% vs 40% today).
- Interest payments on debt are well covered by earnings (EBIT is 5.9x coverage).
- Astec LifeSciences's level of debt (40%) compared to net worth is satisfactory (less than 40%).
- High level of physical assets or inventory.
management
- The tenure for the Astec LifeSciences board of directors is about average.
- Ashok's remuneration is lower than average for companies of similar size in India.
- Ashok's compensation has been consistent with company performance over the past year, both up more than 20%.
- The average tenure for the Astec LifeSciences management team is over 5 years, this suggests they are a seasoned and experienced team.
- Astec LifeSciences individual insiders have only sold shares in the past 3 months.
misc
- Astec LifeSciences is covered by less than 3 analysts.
- Astec LifeSciences has significant price volatility in the past 3 months.
past
- Astec LifeSciences has delivered over 20% year on year earnings growth in the past 5 years.
- Astec LifeSciences used its assets more efficiently than the IN Chemicals industry average last year based on Return on Assets.
- Astec LifeSciences's earnings growth has exceeded the IN Chemicals industry average in the past year (33.1% vs 9.1%).
- Astec LifeSciences's 1-year earnings growth is less than its 5-year average (33.1% vs 41.9%)
- Astec LifeSciences's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- Astec LifeSciences has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
value
- Astec LifeSciences's share price is below the future cash flow value, and at a moderate discount (> 20%).
- Astec LifeSciences's share price is below the future cash flow value, and at a substantial discount (> 40%).
- 533138 outperformed the Chemicals industry which returned 2.2% over the past year.
- 533138 outperformed the Market in India which returned -14.5% over the past year.
- BSE:533138 is up 26% outperforming the Chemicals industry which returned 6.9% over the past month.
- BSE:533138 is up 26% outperforming the market in India which returned 8% over the past month.
- Astec LifeSciences is overvalued based on assets compared to the IN Chemicals industry average.
- Astec LifeSciences is poor value based on expected growth next year.
- Astec LifeSciences is overvalued based on earnings compared to the IN Chemicals industry average.
- Astec LifeSciences is overvalued based on earnings compared to the India market.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800